• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agency of Health Technology Assessment of Uruguay
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canada’s Drug Agency (CDA-AMC)
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Healthcare Quality Institute
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Regione Emilia Romagna
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [24546 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2025     National Institute for Health and Care Excellence (NICE) Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis. NICE technology appraisal guidance 1096
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Efficacy and safety of pulmonary balloon angioplasty in the treatment of chronic thromboembolic pulmonary hypertension]
2025     NIHR Health Services and Delivery Research programme Implementing routine assessment of perinatal anxiety: case studies
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ceftazidime/avibactam (bacterial infections, several therapeutic indications, from birth to < 3 months) – Assessment according to §35a (para. 1c) Social Code Book V]
2025     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evidence mapping on robotic surgery in benign and malignant pathology]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical practice guideline on deprescribing antidepressants]
2025     NIHR Health Technology Assessment programme A group psychological intervention for postnatal depression in British mothers of South Asian origin – the ROSHNI-2 RCT
2025     NIHR Health Technology Assessment programme Sputum colour charts to guide antibiotic self-treatment of acute exacerbation of chronic obstructive pulmonary disease: the Colour-COPD RCT
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (COPD) – 2nd Addendum to Project A24-79]
2025     Austrian Institute for Health Technology Assessment (AIHTA) Lifileucel (AMTAGVI®) for previously treated unresectable or metastatic melanoma
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical practice guideline (CPG) update palliative care]
2025     NIHR Health Technology Assessment programme Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Faricimab (visual impairment due to macular oedema secondary to retinal vein occlusion) – Addendum to Project A24-85]
2025     Austrian Institute for Health Technology Assessment (AIHTA) Digital health technologies for self-identification of the risk of perinatal mental illness
2025     NIHR Health Technology Assessment programme Behaviour change interventions to promote physical activity in people with intermittent claudication: the OPTIMA systematic review
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Belzutifan (von Hippel-Lindau disease) – Benefit assessment according to §35a Social Code Book V]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Overview – Quebec frequent emergency department users 2022-2023]
2025     NIHR Health Services and Delivery Research programme Co-designing and testing the learn together guidance to support patient and family involvement in patient safety investigations: a mixed-methods study
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Belzutifan (renal cell carcinoma) – Benefit assessment according to §35a Social Code Book V]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Access to breast cancer screening for Québec women aged 40 to 49: issues, considerations and implementation approach]
2025     National Institute for Health and Care Excellence (NICE) Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitable. NICE technology appraisal guidance 1048
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Blinatumomab (refractory ALL, children < 1 year) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2025     NIHR Health Services and Delivery Research programme Accessibility and acceptability of perinatal mental health services for women from ethnic minority groups: a synopsis of the PAAM study
2025     National Institute for Health and Care Excellence (NICE) Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia. NICE technology appraisal guidance 1049
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Blinatumomab (first relapsed ALL, children < 1 year) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2025     NIHR Health Services and Delivery Research programme Strategies to manage emergency ambulance telephone callers with sustained high needs: the STRETCHED mixed-methods evaluation with linked data
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Diagnostic accuracy of ex vivo confocal microscopy during Mohs surgery for basal cell carcinomas]
2025     National Institute for Health and Care Excellence (NICE) Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over. NICE technology appraisal guidance 1050
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Blinatumomab (ALL, adults) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2025     NIHR Health Technology Assessment programme Tumour profiling tests to guide adjuvant chemotherapy decisions in lymph node-positive early breast cancer: a systematic review and economic evaluation
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness of care models based on the incorporation of psychologists in primary care]
2025     National Institute for Health and Care Excellence (NICE) Zolbetuximab with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma. NICE technology appraisal guidance 1046
2025     Andalusian Health Technology Assessment Area (AETSA) [Impact of multidisciplinary hospital teams employing ultrasound-guided vascular access]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Setmelanotide (obesity, children 2 to < 6 years) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2025     NIHR Health Technology Assessment programme Rapid diagnostic tests to inform clinical decision-making for antifungal stewardship in the ICU: a qualitative study with NHS staff, patients, and their legal representatives
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Safety and clinical effectiveness of cryoanalgesia in pediatric patients after surgical intervention for pectus excavatum]
2025     National Institute for Health and Care Excellence (NICE) Atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable (terminated appraisal). NICE technology appraisal guidance 1047
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fedratinib (myelofibrosis, pretreatment with ruxolitinib) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V (expiry of the decision)]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Fetal sex determination using circulating cell-free DNA in cases of genetic risk: repatriation of an analysis carried out outside the province of Quebec]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Branched endovascular prostheses for the treatment of aortic arch pathology]
2025     National Institute for Health and Care Excellence (NICE) 12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites. NICE technology appraisal guidance 1045
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Phonocardiography to rule out coronary heart disease (Addendum to Project E19-09)]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Routine practice data collection for odronextamab (follicular lymphoma) - First addendum to Project A24-17]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Early detection of graft damage in kidney and heart recipient patients using donor-derived free DNA (dd-cfDNA)]
2025     National Institute for Health and Care Excellence (NICE) Alcohol-mediated perivascular renal sympathetic denervation for resistant hypertension. NICE interventional procedures guidance 801
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fosdenopterin (molybdenum cofactor deficiency Type A) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2025     Scottish Health Technologies Group (SHTG) Intelligent Liver Function Testing (iLFT) for the earlier diagnosis of chronic liver disease (CLD)
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Blood testing for cystatin C by immunoturbidimetry]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [CRP apheresis in acute anterior myocardial infarction Addendum to project E22-11]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Seladelpar (primary biliary cholangitis [PBC]) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2025     Scottish Health Technologies Group (SHTG) Optune Gio® tumour-treating field therapy
2025     Health Information and Quality Authority (HIQA) Protocol for a health technology assessment of immunisation against respiratory syncytial virus in Ireland
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Osimertinib (locally advanced, unresectable NSCLC) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Unresectable or metastatic melanoma; assessment according to §35a Social Code Book V; search for disease registries]
2025     NIHR Health Technology Assessment programme Algorithm-based remote monitoring of heart failure risk data in people with cardiac implantable electronic devices: a systematic review and cost-effectiveness analysis
2025     Health Information and Quality Authority (HIQA) The management of acute asthma attack in adults: protocol for a review of international clinical guidelines
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [AR101 (peanut allergy, 1 to 3 years) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Osimertinib (locally advanced, unresectable NSCLC) – Addendum to Project A25-03]
2025     NIHR Health Services and Delivery Research programme Effectiveness and cost-effectiveness of community perinatal mental health services on access, experience, recovery/relapse and obstetric and neonate outcomes: the ESMI-II mixed-methods study
2025     Health Information and Quality Authority (HIQA) The management of obesity in adults: protocol for a review of international clinical guidelines
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exagamglogene autotemcel (transfusion dependent beta thalassaemia) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nirsevimab (prevention of RSV lower respiratory tract disease) – Benefit assessment according to §35a Social Code Book V]
2025     Center for Outcomes Research and Economic Evaluation for Health (C2H) Cost-effectiveness evaluation of Zolbetuximab (Vyloy)
2025     Health Information and Quality Authority (HIQA) Protocol: development of a tool for the collection of costs attributable to infectious disease outbreaks in public acute hospitals
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exagamglogene autotemcel (sickle cell disease) – Assessment according to §35a (para. 1, sentence 11) Social Code]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atogepant (migraine) – Benefit assessment according to §35a Social Code Book V]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Pentobarbital blood determination by HPLC-MS/MS]
2025     Health Information and Quality Authority (HIQA) National guidelines for the economic evaluation of health technologies in Ireland
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lazertinib (NSCLC, first line, in combination with amivantamab) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vibegron (overactive bladder) – Benefit assessment according to §35a Social Code Book V]
2025     Austrian Institute for Health Technology Assessment (AIHTA) Further development of the program on preventive health check-ups: screening for chronic kidney disease – a rapid review of benefits, harms and target populations
2025     Health Information and Quality Authority (HIQA) National guidelines for the budget impact analysis of health technologies in Ireland
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Amivantamab (NSCLC, pretreated) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (systemic light chain amyloidosis) – Benefit assessment according to §35a Social Code Book V]
2025     NIHR Health Services and Delivery Research programme Design and deployment of digital health interventions to reduce the risk of the digital divide and to inform development of the living with COVID recovery: a systematic scoping review
2025     Health Technology Wales (HTW) Permanent implant brachytherapy devices for the treatment of locally advanced, unresectable pancreatic cancer
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Amivantamab (NSCLC, combination with carboplatin and pemetrexed) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Garadacimab (hereditary angioedema) – Benefit assessment according to §35a Social Code Book V]
2025     Norwegian Medical Products Agency (NOMA) Ketamine for acute suicidal ideation. Protocol for a health technology assessment
2025     Health Technology Wales (HTW) At-home video monitoring for the diagnosis and management of epilepsy
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sodium thiosulfate (prevention of ototoxicity induced by cisplatin chemotherapy in solid tumours) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Routine practice data collection for epcoritamab (follicular lymphoma) - First addendum to Project A24-40]
2025     NIHR Health Technology Assessment programme Acceptance and commitment therapy for people living with motor neuron disease: the COMMEND feasibility study and randomised controlled trial
2025     Health Technology Wales (HTW) Use of advanced electrosurgical bipolar vessel sealing systems during hysterectomy compared to other methods for control of bleeding
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Marstacimab (haemophilia A) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ribociclib (breast cancer, adjuvant treatment) – Addendum to Project A24-124]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Mobile applications for pulmonary rehabilitation - chronic obstructive pulmonary disease]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Osimertinib (NSCLC, combination with pemetrexed and platinum-based chemotherapy) – benefit assessment according to §35a Social Code Book V]
2025     Health Technology Wales (HTW) Implantable tibial neuromodulation devices for treatment of urge urinary incontinence
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Marstacimab (haemophilia B) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Acoramidis (transthyretin amyloidosis with cardiomyopathy) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Epcoritamab (diffuse large B-cell lymphoma [DLBCL]) – Addendum to Project A24-108]
2025     NIHR Health Technology Assessment programme Identifying optimal primary prevention interventions for major cardiovascular disease events and all-cause mortality: a systematic review and hierarchical network meta-analysis of RCTs
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (COPD) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sarilumab (polymyalgia rheumatica) – Benefit assessment according to §35a Social Code Book V]
2025     NIHR Health Technology Assessment programme Challenges to overcome in a randomised trial for Proper Understanding of Recurrent Stress Urinary Incontinence Treatment in women: the PURSUIT RCT
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Datopotamab deruxtecan (breast cancer) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sarilumab (polyarticular juvenile idiopathic arthritis) – Benefit assessment according to §35a Social Code Book V]
2025     NIHR Health Technology Assessment programme Ambulatory oxygen for pulmonary fibrosis (OxyPuF): a randomised controlled trial and acceptability study
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Asciminib (chronic myeloid leukaemia) – Benefit assessment according to §35a Social Code Book V]